As longtime AbbVie CEO Rick Gonzalez drives the company through its much-dreaded year of Humira biosimilar erosion, his eventual exit is coming into view. In his 10 years at the helm, the CEO has ...
AbbVie Inc.'s (NYSE:ABBV) stock is trading higher after it released better-than-expected Q1 earnings and raised its 2025 forecast. The company reported an adjusted EPS of $2.46 on Friday, up 6.5% year ...
Hosted on MSN
AbbVie CEO Sees ‘Substantial Momentum’ For Remaining Year After Q2 Earnings Beat: Retail’s No Longer Pessimistic
AbbVie (ABBV) CEO Robert A. Michael on Thursday said that the drug maker is entering the second half of the year with “substantial momentum” after it reported second-quarter earnings that surpassed ...
Michael, who is AbbVie's president and chief operating officer, will become the company's second-ever CEO on July 1. Gonzalez, who has led the company since it spun out from Abbott Laboratories in ...
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 10% year on year to $16.62 billion. Its non-GAAP profit of $2.71 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results